title: Single-day therapy for recurrent genital herpes.
abstract: Genital herpes, an incurable viral disease that can have a devastating impact on affected patients, is a serious public health concern affecting one in four Americans. Episodic treatment with nucleoside analogs for 3-5 days is the most common method of treatment; however, since maximum viral replication occurs within 24 hours after the onset of symptoms, single-day patient-initiated episodic treatment may be a better option. A recent study evaluated the effectiveness of patient-initiated single-day famciclovir versus placebo in the treatment of genital herpes and found that single-day famciclovir decreased healing time and the duration of pain and other symptoms, and increased the proportion of patients who did not progress to a full outbreak. Compared with previous studies, the results of single-day therapy are similar to or better than the results of conventional therapies of 2-5 days' duration. In addition, the convenience of single-day treatment may lead to greater patient adherence and improved overall management of recurrent herpes outbreaks.
authors.affiliation: Department of Dermatology, University of Texas Health Science Center, Houston, Texas 77058, USA. styring@ccstexas.com
authors.forename: Stephen
authors.initials: S
authors.lastname: Tyring
authors.forename: Tim
authors.initials: T
authors.lastname: Berger
authors.forename: Angela
authors.initials: A
authors.lastname: Yen-Moore
authors.forename: Michael
authors.initials: M
authors.lastname: Tharp
authors.forename: Kamal
authors.initials: K
authors.lastname: Hamed
mesh_terms: D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D000077595:Famciclovir; D006558:Herpes Genitalis / Q000188:drug therapy*; D006801:Humans; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D015075:2-Aminopurine; D000077595:Famciclovir